Metzger Michael A 4

What Happened

• Michael A. Metzger, a director of Pyxis Oncology (PYXS), was granted an equity award reported as a derivative acquisition on 2026-03-24. The award covers 45,867 shares/options, reported at $0 in the Form 4 filing. This is a grant (compensation) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-24; Form 4 filed: 2026-03-25 (timely).
• Transaction type/code: A (Grant/award or other acquisition of a derivative).
• Shares/options granted: 45,867; price reported on Form 4: $0; total reported value: $0.
• Vesting: Per footnote, the shares subject to this option will vest 100% on the first anniversary of the grant date, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing details.
• No indication of a 10b5-1 plan, tax-withholding disposition, or cashless sale in this filing.

Context

• This filing reports a director compensation award (an option or similar derivative) that vests in one year. There is no immediate sale or cash exchanged; any future economic benefit depends on vesting and potential exercise terms (exercise price and other terms are not detailed in the provided Form 4 excerpt). Grants to directors are a common form of compensation and do not by themselves indicate buying or selling intent.